Soft tissue sarcoma (STS) is a broad term for cancers that start in soft tissues (muscle, tendons, fat, lymph and blood vessels, and nerves). STS are a rare and heterogeneous group of tumors, arising in connective tissues embryologically derived from the mesenchyme. Soft tissue sarcomas (STSs) comprises entities defined by the World Health Organization (WHO) classification based on a combination of distinctive morphological, immune-histochemical and molecular features.
DelveInsight added a new report titled “Soft Tissue Sarcoma Market Insight, Epidemiology and Market Forecast-2032” to its Market report portfolio. The report provides Soft Tissue Sarcoma (STS) Market Analysis, Market Size Forecast, detailed Epidemiology analysis and forecast, information related to Leading Companies along with the Competitive Analysis.
Some of the key highlights of the Soft Tissue Sarcoma market report are:-
Get a sample report on Soft Tissue Sarcoma Market: https://www.delveinsight.com/report-store/soft-tissue-sarcoma-market
Key Benefits of the Report:
Soft-tissue sarcoma are rare neoplasms that can develop in supporting or connective tissue, such as the muscle, nerves, tendons, blood vessels and fatty and fibrous tissues. They commonly affect the arms, legs, and trunk. They also appear in the stomach and intestines (GIST) as well as behind the abdomen (retroperitoneal sarcomas) and the female reproductive system (gynecological sarcomas). Soft tissue sarcoma epidemiology is segmented by:
The different types of Soft Tissue Sarcoma that are included in the report are Leiomyosarcoma, followed by Fibroblastic sarcomas, and synovial sarcoma. The total Soft Tissue Sarcoma incidence cases in the United States were 2,961 cases of Leiomyosarcoma, followed by Fibroblastic sarcomas, and synovial sarcoma.
The age-specific incidence group include less than 20 years, 21–54 years, and 55 plus years. It is estimated that the most incident age-group for Soft Tissue Sarcoma in the US was 55+ years in 2017. The patients of age groups 21–54 years were observed to be the second-highest in 2017.
The stage-specific incidence in the US estimated the localized stage accounted to be 60% of overall Soft Tissue Sarcoma cases in 2017. There were 7,434 cases of localized type, 2,354 cases of regional type, 1,859 cases of distant type, and 743 cases of unknown type.
The current treatment landscape of STS is mainly dependent on targeted therapy, chemotherapy, anti-angiogenesis drugs, and radiation therapy. But the approved therapies are not up to the mark as they are associated with significant side effects as well as inefficacy.
The launch of the emerging therapies is expected to significantly impact Soft Tissue Sarcoma treatment scenario in the upcoming years (2020–2030). Among the 7MM, US accounts for the largest market size of STS, in comparison to EU5 (United Kingdom, Spain, Italy, France, Spain) and Japan.
Click Here to Get a sample page: https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-market
Soft Tissue Sarcoma Drugs covered
Schedule a free WebEx demo of the report: https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-market
Soft Tissue Sarcoma Companies
Table of contents
1. Key Insights
2. Executive Summary of Soft Tissue Sarcoma
3. Soft Tissue Sarcomas Market Overview at a Glance
4. Soft Tissue Sarcoma Disease Background and Overview
5. Soft Tissue Sarcoma Epidemiology and Patient Population
6. Case Reports
7. Country Wise Soft Tissue Sarcoma Epidemiology
8. Soft Tissue Sarcoma Treatment and Management
9. Unmet Needs in Soft Tissue Sarcoma
10. Soft Tissue Sarcoma Marketed Drugs
11. Soft Tissue Sarcoma Emerging Drugs
12. Soft Tissue Sarcoma 7 Major Market Analysis
13. Soft Tissue Sarcoma Market Outlook: The United States
14. Soft Tissue Sarcoma Market Outlook: Europe
15. Soft-Tissue Sarcoma Market Outlook: Japan
16. Access and Reimbursement Overview of Soft Tissue Sarcoma
17. Market Drivers
18. Market Barriers
19. SWOT Analysis
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +19193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/report-store/soft-tissue-sarcoma-market?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=apr